


Volpara® Scorecard™




Volpara® Scorecard™, powered by Volpara's FDA-cleared TruDensity™ algorithm, is a breast density assessment software that delivers consistent, volumetric insights. It provides clinicians with consistent, objective data to support earlier cancer detection and supplemental imaging recommendations.



Volpara Scorecard: AI-Powered Breast Density Assessment Software

Get objective, AI-powered volumetric density assessments that support clearer screening decisions and more confident follow-up care.



Key patient insights in one place

Women diagnosed during the earliest stages of breast cancer have better outcomes and survival rates.¹ Volpara® Scorecard™ software provides your breast care team with the insights they need to find cancer earlier. Easily accessed from the radiologist's workstation, Volpara Scorecard streamlines your workflow to improve clinical decision-making and create a better patient experience.

3 Breast cancer risk insights, 1 customizable view

ONE

Volpara® TruDensity™

Automated, objective, volumetric breast density measurements and a breast density category for an objective and consistent assessment²

Automatic density assessment



TWO

Volpara® Risk Pathways®*

Tyrer-Cuzick v8 Risk Evaluation Tool to calculate lifetime risk of developing breast cancer³

Lifetime risk



THREE

Suspicious findings score**

Machine learning-based analysis to categorize mammograms by the likelihood of the presence of cancerous lesions⁴

Suspicious findings




Personalized screening approach

* Available as an integration with Volpara® Patient Hub™ software

**Available as an integration with Lunit® INSIGHT MMG or DBT software to customers in the U.S.

Precise measurement for every patient

Breast density isn't just a category. Understand your patients breast tissue composition on a continuous scale for more confidence in your recommended care.



Clinical decision support for personalized breast care

Volpara Scorecard is available to radiologists during mammography interpretation as a DICOM® Secondary Capture Image. This customizable image also includes these features:

- Volpara® TruRadDose™ and Volpara® TruPressure™ clinical functions provide quality control measures for study dose and compression pressure, respectively.
- Integration with Volpara® Patient Hub™ allows a lifetime risk score to be included in DICOM Mammography CAD (SC and SR). Lunit® INSIGHT MMG or DBT integration enables the inclusion of an abnormality score.*
- Alerts indicate when the patient meets high-risk thresholds.

Evidence for essential screening

Referring physicians and insurers require evidence of high breast density. Volpara Scorecard's objective, science-based measures help you triage women at high risk to the screening or diagnostic testing essential for better outcomes.

Effective triage for time and cost savings

Personalized screening scores help the radiologist guide a client with high breast density to essential imaging while they're still in the facility, saving an extra trip and the cost of scheduling an additional appointment.

Combined with Volpara® Analytics™ software, Volpara Scorecard assists in identifying populations with high breast density that may require additional services.

[FIND OUT MORE](#)

About Volpara Scorecard


To see how the new Volpara Scorecard can support your breast screening program, contact your Lunit representative for a live demonstration, or visit our website.

* Additional products required for integration.


Why radiologists choose Volpara's automated breast density assessment:

4-6x


Greater risk for clients with dense breasts to develop breast cancer when compared to those with fatty breasts



Sensitivity in mammographic cancer detection for women with dense breasts when compared to those with fatty breasts



Average agreement with the VDG category*



Average agreement with Volpara's assessment of fatty (a/b) or dense (c/d)*

*By trained, expert radiologists in clinical practice.



Inter-reader agreement





Intra-reader agreement

Visual density assessment is not always consistent.

Getting non-dense vs. dense right



Nearly 75% of patients will be assessed in either the B or C density categories. Accurate classification between a BI-RADS B and C is essential.




Two experts agreed about 65% of the time on a BI-RADS density category in a blind study.⁵

Volpara Scorecard: #1 tool for automated breast density assessment

Research has shown that radiologists who assess breast density visually assign density categories inconsistently.⁶ The objective **TruDensity** algorithm in **Volpara Scorecard** is proven to reduce reader variability. TruDensity automatically assesses the volumetric breast density percentage (VBD%) of each mammogram on a continuous scale. This differentiates each woman on a continuum of density – whether her density is a “high B” or a “low C.” This gives the radiologist important insight to evaluate patients on the dense, non-dense threshold more precisely.



Radiologists typically agree with Volpara's assessment of non-dense (A or B) or dense (C or D) 96% of the time.⁷



Volpara's software is used to assess breast density for more than 6 million women annually.


“We have found Volpara to decrease inter- and intra-observer variation in breast density determination, thereby optimizing the care of our patients.”

Dr. Kathy Schilling, Lynn Women's Health Institute at Boca Raton Regional Hospital, Baptist Health


The Volpara TruDensity physics-based AI algorithm is cleared by the FDA, Health Canada, and TGA (Australia); is CE marked; and has been validated in more than **400 articles and research abstracts**.

Going beyond density inform to understanding + action

Volpara® Thumbnail™ empowers patients to understand their breast density with image-enhanced mammography results letters. Patients are shown two non-diagnostic images of their breasts and an explanation of what their density category means in simple-to-understand terms and visuals.



Scan this QR code with the camera app on your cell phone for more about breast density.



Professional services to lower your burden and unlock success

Lunit experts are available to help breast imaging centers educate referrers and patients, and to maximize the value of dense breast screening programs.

New dense breast screening program development


Project services include:

- Audit workflow, resources, and potential volume
- Goals and KPI identification
- Referrer and patient education
- Quarterly program audits/optimization

Breast density awareness and education services

Project services include:

- Referrer Lunch & Learns
- Ready to use patient education presentations
- Branded, customized digital and printed collateral
- Technologist and front desk scripts/training




What are dense breasts? (Video from the Brem Foundation)



What's next? The Find it Early Act

The nationwide law for density inform did not address insurance coverage for additional lifesaving screenings. The **Find It Early Act** is a new federal bill that was introduced recently to ensure all health insurance plans cover screening and diagnostic breast imaging without out-of-pocket costs for women with dense breasts or higher risk for breast cancer. Sixteen states currently mandate coverage at the state level.



50 states + DC!

Federal density inform ruling effective 9/10/24

33 states + DC

Mandate supplemental imaging/testing coverage and cap costs

5 states

Offer genetic testing as major population health initiatives

▲ State with insurance coverage
■ State-wide genetic testing program

Visit [State Legislation Map | DenseBreast-info, Inc.](#) to review your state's legislative language. Snapshot as of November 2024.

(for informational purposes only, please verify information)

Volpara Risk Pathways provides a smooth workflow for healthcare providers to assess hereditary and lifetime breast cancer risk. Volpara volumetric breast density assessment is the only automated, continuous measure **validated for use** with the Tyrer-Cuzick v8 (TC8) Risk Evaluation Tool.

Volpara interfaces with major genetics labs – including Ambry, Myriad, Natera, and Invitae – to offer the freedom to select a preferred lab or work with multiple labs as needs and/or patient insurance coverage requirements change.

“The key improvement that Volpara brings to density reporting is an objective, reproducible density value that can be used in risk assessment models. These models are increasingly used to determine if a woman qualifies for MRI-based screening, and also to decide if the risk is high enough to warrant preventive therapy to reduce risk.”

Professor Jack Cuzick, developer of TC8

References: 1 Clinical outcomes in very early breast cancer ($\leq 1\text{cm}$): A national population based analysis. Mahvish Muzaffar, Abdul Rafeh Naqash, Nasreen A. Vohra, Darla K. Liles, and Jan H. Wong. Journal of Clinical Oncology 2017 35:15_suppl, e12034-e12034. / 2 Gubern-Merida, A., Kallenberg, M., Platel, B., Mann, R.M., Marti, R. and Karssemeijer, N. (2014) Volumetric Breast Density Estimation from Full-Field Digital Mammograms: A Validation Study. PLoS ONE; 9: e85952. / 3 Terry, M.B. et al. 10-year performance of four models of breast cancer risk: a validation study. Lancet Oncol 20, 504–517 (2019). / 4 Rodriguez-Ruiz et al., Can we reduce the workload of mammographic screening by automatic identification of normal exams with artificial intelligence? A feasibility study. Eur Radiol. 2019; 29(9): pp 4825–4832. Panto, Ritu & Shrestha, Shanta & Jha, Anamika. (2020). Glandular density distribution in digital mammography. Grande Medical Journal. 2. 5-9. 10.3126/gmj.v2i1.45080. / 5 Ciattò et al, The Breast 2005. / 6 Redondo A, Comas M, Macià F, Ferrer F, Murta-Nascimento C, Maristany MT, Molins E, Sala M, Castells X. Inter- and intraradiologist variability in the BI-RADS assessment and breast density categories for screening mammograms. Br J Radiol. 2012 Nov;85(1019):1465–70. doi: 10.1259/bjrad.21256379. Epub 2012 Sep 19. PMID: 22993385; PMCID: PMC3500788. / 7 Data on company file. Analysis from 36,642 cases across four clinics.

Copyright © Lunit International Ltd. 2025. All rights reserved. BI-RADS is a registered trademark of the American College of Radiology and American College of Radiology Association. DICOM is a registered trademark of the National Electrical Manufacturers Association. All rights reserved.

Lunit, Inc. owns, uses or enforces the following trademarks of service marks: Lunit, Lunit INSIGHT MMG, and Lunit INSIGHT DBT. The products described are CE certified in accordance with applicable EU standards and regulations. The product fulfills the requirements for CE certification. 5F, 374 Gangnam-daero, Gangnam-gu, Seoul, 06241, Republic of Korea
mfk5877-6



Conquering Cancer through AI

Lunit Inc.
374, Gangnam-daero, Gangnam-gu
Seoul, South Korea 06241

© 2025 Lunit Inc. All rights reserved.

